Increased Risks for Cardiovascular Events in Men with Prostate Cancer on GnRH Agonist Therapy

Traditional hormone therapy usually consists of two types of drugs; GnRH agonists (like Lupron and Zoladex) and antiandrogens (Casodex). Although they both are drugs that manipulate the hormone system their modes of action are different. GnRH agonists block the production of the male hormone testosterone while the antiandrogen drug blocks the ability of the prostate [...]

Efficacy of a Modified Androgen Blockade in Prostate Cancer Patients with Biochemical Failure

How to best treat men with a prostate cancer PSA only recurrence (biochemical recurrence) still remains controversial. Hormone therapy (ADT) using a combination of a 5-alpha reductase inhibitor and an antiandrogen without conventional gonadal androgen suppression (where testosterone levels are not suppressed) may allow control of the prostate-specific antigen (PSA) with less morbidity. METHODS: In [...]

New Phase 2 Trials For MDV3100 Begins & Another To Start Soon – On The Horizon

It was announced today that the first patient in the TERRAIN study received their first dose in the Phase 2 trial of the investigational drug MDV3100 . MDV3100 is a triple-acting oral androgen receptor antagonist that I have writing about as a drug “On The Horizon”. Triple-acting means that it blocks testosterone binding to the [...]

Should Degarelix Be Accompanied By An Antiandrogen?

On the Advanced Prostate Cancer Listserv there was a question raised about the need to use an antiandrogen (bicalutamide/Casodex, flutamide/Eulexin, or nilutamide/Nilandron) along with degarelix, the recently approved LHRH antagonist (a drug that halts the production of testicular androgens). Doctors who are knowledgeable about the use of LHRH antagonists (Zoladex, Lupron, Eligard, Viadur and Firmagon [...]

Go to Top